Forbes January 13, 2020
Bruce Y. Lee

Clinical trials can be very expensive, time consuming, and difficult to recruit for and run. They also can be far from perfect, yielding results that don’t really match what happens in the “real world.” In some cases, they can put patients at significant risk. Otherwise, no problem, right?

For years, medicine and health care have relied on the randomized clinical trial as the “gold standard” to evaluating an intervention, a drug, a medical device, or some other product. But in actuality, this standard has often been more gold-plated than true gold for the reasons mentioned above. Therefore, there’s been a need for new approaches to help fill the current gaps left by clinical trials. And something called The Living Heart...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Precision Medicine, Provider, Technology
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
AstraZeneca plans independent drug supply chains for US and China, CEO says
Digital Platforms Streamline Medication Access and Delivery
Pharma Pulse 3/27/24: Patients Hate ‘Forever’ Drugs—Is Wegovy Different? Low Melatonin Can Increase Risk of Neurological Disorders & more
Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Share This Article